Pollen Williamson

FDA Statement on Abuse-Deterrent Opioids

by Pollen Williamson | Nov 21, 2017 | Content

FDA Commissioner Scott Gottlieb, MD, has issued a statement on the steps being taken to promote development of generic versions of opioids formulated to deter abuse. “As we continue to confront the staggering human and economic toll created by opioid abuse and...

Webinar Series: Support for Hospital Opioid Use Treatment (SHOUT)

by Pollen Williamson | Nov 21, 2017 | Events

Hospitalizations for people with opioid use disorder represent an ideal time to start treatment. Project SHOUT helps hospitals start buprenorphine and methadone services, with coaching from University of California San Francisco specialists. The SHOUT webinar series...

Reducing Opioid Use While Managing Chronic Pain

by Pollen Williamson | Nov 12, 2017 | Content

A $9 million study, led by RTI International, aims to provide strategies for reducing opioid use among patients who are not benefitting from it while ensuring access to those who are benefitting. RTI will collaborate with the Mid-South Clinical Data Research...

Concurrent Use of Opioids and Benzodiazepines

by Pollen Williamson | Nov 9, 2017 | Content

Researchers analyzed laboratory data (Quest Diagnostics) from over 140,000 patients prescribed opioids with reported medication lists to assess co-occurrence of substances and medications. Among the findings, more than 20% were positive for both opioids and...

State Distributes 40K Doses of Naloxone

by Pollen Williamson | Nov 4, 2017 | Content

North Carolina is making nearly 40,000 more units of life-saving medication available to help fight the opioid epidemic, Governor Roy Cooper announced today. The state has purchased naloxone, which can reverse opioid overdose, to help reduce the number of...